Sirtex Medical: Biotech Market Spotlight
Friday, 23 October, 2009
Oncology treatment company, Sirtex Medical (ASX:SRX) has continued to perform well, gaining 23c or 3.85% today as of 3pm to $6.20.
This follows a week of strong gains following an announcement on Monday of a 68% increase in operating profit from $3.25 million to $5.47 million for the last financial quarter.
The company also announced a dividend of 2c per share plus a special dividend of 5c per share to be paid in December.
Sirtex Medical, which manufactures SIR-Spheres for the treatment of liver cancer, saw revenues raise from $12.29 million to $16.47 million in the last quarter, a lift of 34%, in spite of a strengthening Australian dollar.
The company's stock has performed well over since the start of the year, with it seeing a 280% lift since January 2.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
